vs

Side-by-side financial comparison of EXACT SCIENCES CORP (EXAS) and Lineage, Inc. (LINE). Click either name above to swap in a different company.

Lineage, Inc. is the larger business by last-quarter revenue ($1.4B vs $878.4M, roughly 1.6× EXACT SCIENCES CORP). Lineage, Inc. runs the higher net margin — -7.3% vs -9.8%, a 2.5% gap on every dollar of revenue. On growth, EXACT SCIENCES CORP posted the faster year-over-year revenue change (23.1% vs 3.1%). EXACT SCIENCES CORP produced more free cash flow last quarter ($120.4M vs $35.0M).

Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.

Norwegian Cruise Line Holdings (NCLH) is a holding company that is based in the United States and domiciled in Bermuda. It operates three cruise lines as wholly owned subsidiaries: Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. With its subsidiaries combined, it is the third-largest cruise operator in the world. It is a publicly traded company listed on the New York Stock Exchange.

EXAS vs LINE — Head-to-Head

Bigger by revenue
LINE
LINE
1.6× larger
LINE
$1.4B
$878.4M
EXAS
Growing faster (revenue YoY)
EXAS
EXAS
+20.0% gap
EXAS
23.1%
3.1%
LINE
Higher net margin
LINE
LINE
2.5% more per $
LINE
-7.3%
-9.8%
EXAS
More free cash flow
EXAS
EXAS
$85.4M more FCF
EXAS
$120.4M
$35.0M
LINE

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
EXAS
EXAS
LINE
LINE
Revenue
$878.4M
$1.4B
Net Profit
$-86.0M
$-100.0M
Gross Margin
70.1%
32.3%
Operating Margin
-9.4%
2.5%
Net Margin
-9.8%
-7.3%
Revenue YoY
23.1%
3.1%
Net Profit YoY
90.1%
79.4%
EPS (diluted)
$-0.45
$-0.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXAS
EXAS
LINE
LINE
Q4 25
$878.4M
Q3 25
$850.7M
$1.4B
Q2 25
$811.1M
$1.4B
Q1 25
$706.8M
$1.3B
Q4 24
$713.4M
$1.3B
Q3 24
$708.7M
$1.3B
Q2 24
$699.3M
$1.3B
Q1 24
$637.5M
$1.3B
Net Profit
EXAS
EXAS
LINE
LINE
Q4 25
$-86.0M
Q3 25
$-19.6M
$-100.0M
Q2 25
$-1.2M
$-6.0M
Q1 25
$-101.2M
$0
Q4 24
$-864.6M
$-71.0M
Q3 24
$-38.2M
$-485.0M
Q2 24
$-15.8M
$-68.0M
Q1 24
$-110.2M
$-40.0M
Gross Margin
EXAS
EXAS
LINE
LINE
Q4 25
70.1%
Q3 25
68.6%
32.3%
Q2 25
69.3%
31.9%
Q1 25
70.8%
32.2%
Q4 24
69.0%
32.3%
Q3 24
69.4%
32.8%
Q2 24
69.8%
33.4%
Q1 24
70.0%
33.4%
Operating Margin
EXAS
EXAS
LINE
LINE
Q4 25
-9.4%
Q3 25
-3.0%
2.5%
Q2 25
-0.3%
1.7%
Q1 25
-13.6%
4.3%
Q4 24
-122.8%
-1.6%
Q3 24
-5.6%
-38.6%
Q2 24
-3.8%
5.5%
Q1 24
-16.7%
7.6%
Net Margin
EXAS
EXAS
LINE
LINE
Q4 25
-9.8%
Q3 25
-2.3%
-7.3%
Q2 25
-0.1%
-0.4%
Q1 25
-14.3%
Q4 24
-121.2%
-5.3%
Q3 24
-5.4%
-36.3%
Q2 24
-2.3%
-5.1%
Q1 24
-17.3%
-3.0%
EPS (diluted)
EXAS
EXAS
LINE
LINE
Q4 25
$-0.45
Q3 25
$-0.10
$-0.44
Q2 25
$-0.01
$-0.03
Q1 25
$-0.54
$0.01
Q4 24
$-4.69
$-0.52
Q3 24
$-0.21
$-2.44
Q2 24
$-0.09
$-0.46
Q1 24
$-0.60
$-0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXAS
EXAS
LINE
LINE
Cash + ST InvestmentsLiquidity on hand
$964.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.4B
$8.4B
Total Assets
$5.9B
$19.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXAS
EXAS
LINE
LINE
Q4 25
$964.7M
Q3 25
$1.0B
Q2 25
$858.4M
Q1 25
$786.2M
Q4 24
$1.0B
$173.0M
Q3 24
$1.0B
$409.0M
Q2 24
$946.8M
$73.0M
Q1 24
$652.1M
Stockholders' Equity
EXAS
EXAS
LINE
LINE
Q4 25
$2.4B
Q3 25
$2.5B
$8.4B
Q2 25
$2.5B
$8.6B
Q1 25
$2.4B
$8.6B
Q4 24
$2.4B
$8.6B
Q3 24
$3.2B
$9.0B
Q2 24
$3.2B
$4.9B
Q1 24
$3.1B
$5.6B
Total Assets
EXAS
EXAS
LINE
LINE
Q4 25
$5.9B
Q3 25
$5.9B
$19.2B
Q2 25
$5.8B
$19.4B
Q1 25
$5.7B
$18.8B
Q4 24
$5.9B
$18.7B
Q3 24
$6.7B
$19.3B
Q2 24
$6.7B
$18.8B
Q1 24
$6.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXAS
EXAS
LINE
LINE
Operating Cash FlowLast quarter
$151.7M
$230.0M
Free Cash FlowOCF − Capex
$120.4M
$35.0M
FCF MarginFCF / Revenue
13.7%
2.5%
Capex IntensityCapex / Revenue
3.6%
14.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$356.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXAS
EXAS
LINE
LINE
Q4 25
$151.7M
Q3 25
$219.9M
$230.0M
Q2 25
$89.0M
$258.0M
Q1 25
$30.8M
$139.0M
Q4 24
$47.1M
Q3 24
$138.7M
$186.0M
Q2 24
$107.1M
$155.0M
Q1 24
$-82.3M
$105.0M
Free Cash Flow
EXAS
EXAS
LINE
LINE
Q4 25
$120.4M
Q3 25
$190.0M
$35.0M
Q2 25
$46.7M
$95.0M
Q1 25
$-365.0K
$-12.0M
Q4 24
$10.7M
Q3 24
$112.6M
$33.0M
Q2 24
$71.2M
$-31.0M
Q1 24
$-120.0M
$-42.0M
FCF Margin
EXAS
EXAS
LINE
LINE
Q4 25
13.7%
Q3 25
22.3%
2.5%
Q2 25
5.8%
7.0%
Q1 25
-0.1%
-0.9%
Q4 24
1.5%
Q3 24
15.9%
2.5%
Q2 24
10.2%
-2.3%
Q1 24
-18.8%
-3.2%
Capex Intensity
EXAS
EXAS
LINE
LINE
Q4 25
3.6%
Q3 25
3.5%
14.2%
Q2 25
5.2%
12.1%
Q1 25
4.4%
11.7%
Q4 24
5.1%
Q3 24
3.7%
11.5%
Q2 24
5.1%
13.9%
Q1 24
5.9%
11.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXAS
EXAS

Screening$695.1M79%
Precision Oncology$183.2M21%

LINE
LINE

Warehousing Operations$883.0M64%
Other$308.0M22%
Warehouse Lease$60.0M4%
Food Sales$52.0M4%
E Commerce And Other$46.0M3%
Railcar Lease$23.0M2%
Service Other$5.0M0%

Related Comparisons